Substituted Pyrrolidines and Methods of Use
US-2018099932-A1 · Apr 12, 2018 · US
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10844041B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10844041-B2 |
| Application number | US-202016878416-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2020 |
| Priority date | Sep 14, 2017 |
| Publication date | Nov 24, 2020 |
| Grant date | Nov 24, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention discloses compounds of Formula (I), wherein A 1 , R 1 , R 2 , R 3 , R 4 , and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
First claim
Opening claim text (preview).
We claim: 1. 1-{5-ethyl-2-[(propan-2-yl)oxy]pyridin-3-yl}-N-(2-methylquinoline-5-sulfonyl)cyclopropane-1-carboxamide. 2. 1-{5 ethyl-2-[(propan-2-yl)oxy]pyridin-3-yl}-N-(2-methylquinoline-5-sulfonyl)cyclopropane-1-carboxamide or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07D215/36Primary
Sulfur atoms (C07D215/24 takes precedence) · CPC title
Ortho-condensed systems · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Drugs for disorders of the respiratory system · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10844041B2 cover?
- The invention discloses compounds of Formula (I), wherein A 1 , R 1 , R 2 , R 3 , R 4 , and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the inven…
- Who is the assignee on this patent?
- Abbvie Overseas Sarl, Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D215/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).